Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00944892 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Osteoarthritis of the Knee
A Phase 1 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 200
- Enrollment target
NCT00944892 is a Phase 1 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 200 participants.
The verdict
NCT00944892, a Phase 1 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 200 participants
- Enrollment target
Study Summary
This is a double-blind, prospective, randomized study in which patients will be randomized to 1 of 4 treatment arms (3 active and 1 placebo). Each patient will receive two doses of active medication or placebo, with study drug administered intravenously (IV). The primary goal of the study is to assess the safety and tolerability of repeat administrations of REGN475 compared to placebo in patients with osteoarthritis (OA) of the knee.
Interventions
- OTHER Placebo
- DRUG REGN475
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2009-08 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00944892
The ClinicalTrials.gov registry entry for NCT00944892 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00944892 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00944892 about?
NCT00944892 is a clinical study titled "A Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Osteoarthritis of the Knee". This is a double-blind, prospective, randomized study in which patients will be randomized to 1 of 4 treatment arms (3 active and 1 placebo). Each patient will receive two doses of active medication or placebo, with study drug administered intravenously (IV). The primary goal of the study is to ass...
What is the current status of trial NCT00944892?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2009-08. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00944892?
The interventions under investigation include: Placebo (OTHER), REGN475 (DRUG).
Who is sponsoring clinical trial NCT00944892?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.